FindTrial
Sign In

Randomised controlled trial of nebulised and metered dose inhaler via spacer salbutamol in acute moderate to severe asthma

Randomised controlled trial of nebulised and metered dose inhaler via spacer salbutamol in acute moderate to severe asthma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN46758872
Enrollment
Unknown
Registered
2004-09-30
Start date
2003-03-01
Completion date
Unknown
Last updated
2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory: Asthma Respiratory Asthma

Interventions

Patients with acute moderate to severe asthma will be randomised to receive inhaled salbutamol either by gas driven nebuliser or by metered dose inhaler and spacer device. Patients will be given oxyge

Sponsors

Department of Health
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients presenting to the emergency department with acute moderate to severe asthma. They will have auscultatory expiratory wheeze and dyspnoea. The severity of their asthma will be determined by reference to the British Thoracic Society (BTS) guidelines on the management of acute asthma. Patients will be excluded if they have any life threatening features as defined in the BTS guidelines.

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

MeasureTime frame
Main outcome measure peak expiratory flow rate (PEFR) (baseline - 15 minutes post salbutamol) and (baseline - 15 minutes post second dose of salbutamol)—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026